Discussion of outcomes for patients with del(17p) or TP53 mutations who have been treated with first-line BTK inhibitors such as ibrutinib or acalabrutinib.
Discussion of outcomes for patients with del(17p) or TP53 mutations who have been treated with first-line BTK inhibitors such as ibrutinib or acalabrutinib.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
